The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The administration of single oral doses of delta‐9‐tetrahydrocannabinol (THC) to patients with cancer pain demonstrated a mild analgesic effect. At a dose of 20 mg, however, THC induced side effects that would prohibit its therapeutic use including somnolence, dizziness, ataxia, and blurred vision. Alarming adverse reactions were also observed at this dose. THC, 10 mg, was well tolerated and, despite its sedative effect, may have analgesic potential.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Keele, K. D. (1948) · The Lancet · doi:10.1016/s0140-6736(48)91787-5 · Cited by 241
Ames, F. (1958) · Journal of Mental Science · doi:10.1192/bjp.104.437.972 · Cited by 184
Snyder, S. H. (1971) · Medical Entomology and Zoology · Cited by 30
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…beneficial effects of cannabis or synthetic derivatives of THC in pain associated with multiple sclerosis, cancer, neuropathies, and HIV infection (Noyes et al., 1975a,b; Martyn et al., 1995; Consroe et al., 1997; Hamann and di Vadi, 1999; Ware et al., 2003; Rudich et al., 2003; Ware and…”
BackgroundPharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
“Spasticity due to spinal cord injury[25,290,291] and multiple sclerosis,[25,291-296] chronic painful conditions, especially neurogenic pain,[290,291,297-301] movement disorders (including Tourette’s syndrome, dystonia and levodopa-induced dyskinesia),[200,302-308] asthma[30,309,310] and glaucoma[28,311-314] can be reg…”
BackgroundCannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
“Somnolence 8 (13) 8 (14) 6 (10) Dizziness 7 (12) 7 (12) 3 (5) Confusion 4 (7) 1 (2) 1 (2) Nausea 6 (10) 4 (7) 4 (7) Vomiting 3 (5) 4 (7) 2 (3) Raised gamma GT 2 (3) 5 (9) 1 (2) Hypercalcemia 0 0 3 (5) Hypotension 3 (5) 0 0”
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
“However, drowsiness and onfusion were frequent (Noyes et al., 1975a,b).”
BackgroundMethodSvendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Campbell, F. A., Tramèr, M. R., Carroll, D., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.13 · Cited by 423
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411
Endocannabinoid signaling system and brain reward: emphasis on dopamine
GARDNER, E. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.032 · Cited by 387
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
“Zajicek et al.10† Multiple sclerosis 630 50 (18–64) 34 15 wk Nervous system disorders: 710/1849 (38.4) Zajicek et al.11† Multiple sclerosis 611 50 (18–64) 34 37 wk Nervous system disorders: 124/655 (18.9) Carroll et al.46 Idiopathic Parkinson disease 19 67 (51–78) 63 4 wk Nervous system disorders: 17/38 (45) Crossover…”
BackgroundInfluentialKarst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain
Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., & Fishman, S. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.12.010 · Cited by 327
Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats
Lichtman, A. H., Dimen, K. R., & Martin, B. R. (1995) · Psychopharmacology · doi:10.1007/bf02246292 · Cited by 311
“Although the cannabinoids possess analgesic (Noyes et al. 1975), antiemetic (Gralla et al.”
BackgroundThe Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Synergistic interactions between cannabinoid and opioid analgesics
Cichewicz, D. L. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.038 · Cited by 305
“Early studies indicated that oral doses of THC were no more effective than codeine for pain, and produced a significant amount of dysphoric side effects (Noyes et al., 1975; Campbell et al., 2001).”
BackgroundAviram, J. (2017) · Pain Physician · doi:10.36076/ppj.20.5.e755 · Cited by 305
Nugent, S. M., Morasco, B. J., O'Neil, M. E., Freeman, M., Low, A., Kondo, K., Elven, C., Zakher, B., Motu'apuaka, M., Paynter, R., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0155 · Cited by 301
“Table 2 summarizes findings, including the ROB rating, by pain subgroup.”
BackgroundInfluentialManzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283
Therapeutic aspects of cannabis and cannabinoids
Robson, P. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.107 · Cited by 265
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on Opioid Therapy
Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., & Jamison, R. N. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.10.018 · Cited by 257
Wallace, M., Schulteis, G., Atkinson, J. H., Wolfson, T., Lazzaretto, D., Bentley, H., Gouaux, B., & Abramson, I. (2007) · Anesthesiology · doi:10.1097/01.anes.0000286986.92475.b7 · Cited by 252
Baron, E. P. (2018) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 251
Cannabinoid Transmission and Reward-Related Events
Gardner, E. L., & Vorel, S. R. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0219 · Cited by 250
Adjuvant Analgesics in Cancer Pain Management
Lussier, D., Huskey, A. G., & Portenoy, R. K. (2004) · The Oncologist · doi:10.1634/theoncologist.9-5-571 · Cited by 249
Molecular Pharmacology of Phytocannabinoids
Turner, S. E., Williams, C. M., Iversen, L., & Whalley, B. J. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_3 · Cited by 238
Johnson, J. R., Lossignol, D., Burnell-Nugent, M., & Fallon, M. T. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2012.07.014 · Cited by 236
Lichtman, A. H., Lux, E. A., McQuade, R., Rossetti, S., Sanchez, R., Sun, W., Wright, S., Kornyeyeva, E., & Fallon, M. T. (2018) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2017.09.001 · Cited by 234
“Among the > 100 CBs present in Cannabis sativa L plants, ∆(9)-tetrahydrocannabinol (THC) has shown promise in relieving cancer-related pain (11, 12).”
Systematic Review and Meta-analysis of Cannabis Treatment for Chronic Pain
Martín-Sánchez, E., Furukawa, T. A., Taylor, J., & Martin, J. L. R. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00703.x · Cited by 225
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 222
“The administration of single oral doses of THC to patients with cancer pain demonstrated a mild analgesic effect.(86,87) Patients who suffer from pain also tend to self-medicate with marijuana.”
Ramer, R., & Hinz, B. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm268 · Cited by 222
Abrams, D., & Guzman, M. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.108 · Cited by 219
Fisher, E., Moore, R. A., Fogarty, A. E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E., Rice, A. S. C., Rowbotham, M., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000001929 · Cited by 215
“14 Noyes et al.(51) 36 5 THC (10 mg, 20 mg) Placebo/Codeine 0.”
BackgroundPharmacological actions and therapeutic uses of cannabis and cannabinoids
Kumar, R. N., Chambers, W. A., & Pertwee, R. G. (2001) · Anaesthesia · doi:10.1046/j.1365-2044.2001.02269.x · Cited by 218
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x158066 · Cited by 216
Medicinal Use of Cannabis: History and Current Status
Kalant, H. (2001) · Pain Research and Management · doi:10.1155/2001/469629 · Cited by 212
Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., & Brenneisen, R. (2003) · Pain · doi:10.1016/s0304-3959(03)00163-5 · Cited by 209
“Oral doses of 15 and 20 mg THC resulted in a significant reduction of cancer pain (Noyes et al., 1975a).”
BackgroundCannabis use in HIV for pain and other medical symptoms
Woolridge, E., Barton, S., Samuel, J., Osorio, J., Dougherty, A., & Holdcroft, A. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.011 · Cited by 208
Pertwee, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.7.1553 · Cited by 208
“In the area of pain relief, there is a limited amount of human data to suggest that cannabinoids are effective against postoperative, cancer and phantom limb pain [89-92] as well as against pain associated with multiple sclerosis or spinal cord injury [75,87,93-95].”
BackgroundBaron, E. P. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 206
“Delta-9-THC doses of 15-20 mg have been shown to be comparable to the analgesic effects of codeine 60-120 mg.(150) Therapeutic uses of cannabis are reported in a wide range of chronic pain disorders as detailed and referenced in Table 1.”
BackgroundPertwee, R. G. (2005) · The AAPS Journal · doi:10.1208/aapsj070364 · Cited by 203
FRYTAK, S., MOERTEL, C. G., O'FALLON, J. R., RUBIN, J., CREAGAN, E. T., O'CONNELL, M. J., SCHUTT, A. J., & SCHWARTAU, N. W. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-6-825 · Cited by 201
The endocannabinoid system and cancer: therapeutic implication
Guindon, J., & Hohmann, A. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01327.x · Cited by 200
Häuser, W., Finn, D. P., Kalso, E., Krcevski‐Skvarc, N., Kress, H., Morlion, B., Perrot, S., Schäfer, M., Wells, C., & Brill, S. (2018) · European Journal of Pain · doi:10.1002/ejp.1297 · Cited by 199
Tang, Z., Kong, N., Ouyang, J., Feng, C., Kim, N. Y., Ji, X., Wang, C., Farokhzad, O. C., Zhang, H., & Tao, W. (2020) · Matter · doi:10.1016/j.matt.2019.12.007 · Cited by 197
Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain
Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., & Rowbotham, D. J. (2003) · Pain · doi:10.1016/s0304-3959(03)00331-2 · Cited by 184
“In 1975, it was suggested that 10 mg of d-9-THC may have analgesic effects in patients with advanced cancer but the study was poorly controlled and relatively insensitive (Noyes et al., 1975).”
BackgroundCannabinoids and multiple sclerosis
Pertwee, R. G. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00255-3 · Cited by 181
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
“Further subgroup analyses indicated that compared to placebo, dronabinol [10, 11, 95, 106, 139, 150, 161, 12, 23, 34, 45, 56, 72, 73, 84] and nabiximols [10, 33–44, 46–52] were associated with significant improvements and moderate evidence (Fig.”
ResultBaron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 177
Endocannabinoids in the retina: From marijuana to neuroprotection
Yazulla, S. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.07.002 · Cited by 177
“Noyes et al. (1975) reported that 10 mg of THC was a mild analgesic for cancer pain but 20 mg of THC produced side effects that included blurred vision.”
BackgroundCannabinoid Mechanisms of Pain Suppression
Walker, J. M., & Hohmann, A. G. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_17 · Cited by 176
Walker, J. M., & Huang, S. M. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00252-8 · Cited by 176
Cannabinoids and cancer: causation, remediation, and palliation
Hall, W., Christie, M., & Currow, D. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01711-5 · Cited by 170
Synergistic interactions of endogenous opioids and cannabinoid systems
Welch, S. P., & Eads, M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01908-3 · Cited by 169
Holdcroft, A., Maze, M., Doré, C., Tebbs, S., & Thompson, S. (2006) · Anesthesiology · doi:10.1097/00000542-200605000-00021 · Cited by 166
Established and potential therapeutic applications of cannabinoids in oncology
Walsh, D., Nelson, K. A., & Mahmoud, F. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0387-7 · Cited by 163
“dose was comparable to both doses of codeine for analgesic efficacy [29].”
Systematic review and meta‐analysis of cannabinoids in palliative medicine
Mücke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H., Radbruch, L., Häuser, W., & Conrad, R. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12273 · Cited by 158
Evaluation of Intramuscular Levonantradol and Placebo in Acute Postoperative Pain
JAIN, A. K., RYAN, J. R., McMAHON, F. G., & SMITH, G. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02610.x · Cited by 150
Endogenous cannabinoids as an aversive or counter-rewarding system in the rat
Sañudo-Peña, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., & Walker, J. M. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13424-3 · Cited by 163
Debbarma, G., & Acharya, P. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15489-8.00002-5 · Cited by 148
Cannabinoids and autoimmune diseases: A systematic review
Katchan, V., David, P., & Shoenfeld, Y. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.02.008 · Cited by 171
Addictive potential of cannabinoids: the underlying neurobiology
Gardner, E. L. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00162-7 · Cited by 152
Strategies for the Treatment of Cancer Pain in the New Millennium
Ripamonti, C. I., & Dickerson, E. D. (2001) · Drugs · doi:10.2165/00003495-200161070-00005 · Cited by 136
“Pain scores for the low doses of THC and codeine (THC 10mg and codeine 60mg) and the high doses of both drugs (THC 20mg, and codeine 120mg) were comparable.[243] Li et al.”
BackgroundCannabinoids for adult cancer-related pain: systematic review and meta-analysis
Boland, E. G., Bennett, M., Allgar, V. L., & Boland, J. W. (2020) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2019-002032 · Cited by 148
Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain
Lucas, P. (2012) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2012.684624 · Cited by 131
“The results suggest that 10 mg THC was slightly less effective than 60 mg codeine, and that 20 mg THC was slightly more effective than 120 mg of codeine (Noyes et al. 1975b).”
BackgroundKramer, J. L. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21260 · Cited by 130
“A study of patients with cancer pain found that THC at a dose of 10 mg had a mild analgesic effect.(85) In a placebo-controlled dose escalation study, pain relief over that of the placebo was noted only at doses of 15 mg and 20 mg.”
BackgroundKraft, B., Frickey, N. A., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., & Kress, H. G. (2008) · Anesthesiology · doi:10.1097/aln.0b013e31817881e1 · Cited by 129
Therapeutic potential of cannabis in pain medicine
Hosking, R., & Zajicek, J. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen119 · Cited by 138
Therapeutic potential of cannabinoid medicines
Robson, P. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1529 · Cited by 140
Medical Marijuana: Clearing Away the Smoke
Grant, I., Atkinson, J. H., Gouaux, B. D., & Wilsey, B. L. (2012) · The Open Neurology Journal · doi:10.2174/1874205x01206010018 · Cited by 134
“, THC 10mg) outperformed placebo and were analgesically equivalent to codeine 60mg; higher doses (THC 20mg) were comparable to codeine 120mg, but had a much higher incidence of adverse effects, particularly sedation [2].”
Health consequences of acute and chronic marihuana use
Maykut, M. O. (1985) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(85)90085-5 · Cited by 136
Antinociceptive, subjective and behavioral effects of smoked marijuana in humans
Greenwald, M. K., & Stitzer, M. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00128-3 · Cited by 131
Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190083 · Cited by 117
Russo, E. (1998) · Pain · doi:10.1016/s0304-3959(98)00033-5 · Cited by 117
“However, despite the justifiable success of sumatriptan in treating acute migraine, problems remain.”
BackgroundCannabinoid Transmission and Pain Perception
Martin, B. R., & Lichtman, A. H. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0218 · Cited by 117
Kehl, L. J., Hamamoto, D. T., Wacnik, P. W., Croft, D. L., Norsted, B. D., Wilcox, G. L., & Simone, D. A. (2003) · Pain · doi:10.1016/s0304-3959(02)00450-5 · Cited by 115
“Scattered reports suggest that cannabinoids exhibit analgesic effects in patients with cancer (Noyes et al., 1975; Staquet et al., 1978) and chronic muscle pain (Petro, 1980), but these evaluations have been of a limited nature.”
BackgroundCannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142
“…receptor agonist L-nantradol is effective against acute postoperative pain (Jain et al., 1981), that D9-THC (10 mg p.o.) can relieve cancer pain (Noyes et al., 1975a, 1975b), and that oral cannabis had a morphine-sparing effect in a patient suffering from severe chronic abdominal pain…”
BackgroundMedical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence
Jensen, B., Chen, J. L., Furnish, T. J., & Wallace, M. S. (2015) · Current Pain and Headache Reports · doi:10.1007/s11916-015-0524-x · Cited by 126
Cannabinoids for Symptom Management and Cancer Therapy: The Evidence
Davis, M. P. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0094 · Cited by 111
Marijuana and Medicine: Assessing the Science Base
Institute of Medicine (1999) · National Academies Press eBooks · doi:10.17226/6376 · Cited by 270
Cannabinoids modulate pain by multiple mechanisms of action
Richardson, J. D. (2000) · The Journal of Pain · doi:10.1016/s1526-5900(00)90082-8 · Cited by 109
Effect of Dronabinol on Central Neuropathic Pain After Spinal Cord Injury: A Pilot Study
Rintala, D. H., Fiess, R. N., Tan, G., Holmes, S. A., & Bruel, B. M. (2010) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3181f1c4ec · Cited by 109
“The initial and additional doses of 5 mg each were selected, in part, based on a study by Noyes et al.17 in which it was found that 10 mg doses of THC were well tolerated.”
MethodFrom phosphorus to phosphorene: Applications in disease theranostics
Zhu, Y., Xie, Z., Li, J., Liu, Y., Li, C., Liang, W., Huang, W., Kang, J., Cheng, F., Kang, L., et al. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214110 · Cited by 106
Lever, I. J., & Rice, A. S. C. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_10 · Cited by 115
Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception
Palazzo, E., Marabese, I., de Novellis, V., Oliva, P., Rossi, F., Berrino, L., Rossi, F., & Maione, S. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00160-x · Cited by 113
Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine
Roberts, J. D., Gennings, C., & Shih, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.036 · Cited by 103
“In a study of patients with disease-related chronic pain, the combination of Δ 9 -THC 10 mg and aspirin 600 mg was a more potent analgesic than either Δ 9 - THC or aspirin alone (Noyes et al., 1975).”
Darmani, N. A. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00531-7 · Cited by 115
YAKSH, T. L. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02612.x · Cited by 103
Effects of cannabis on cognitive function in patients with multiple sclerosis
Honarmand, K., Tierney, M. C., O'Connor, P., & Feinstein, A. (2011) · Neurology · doi:10.1212/wnl.0b013e318212ab0c · Cited by 99
Survey of cannabis use in patients with amyotrophic lateral sclerosis
Amtmann, D., Weydt, P., Johnson, K. L., Jensen, M. P., & Carter, G. T. (2004) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990910402100206 · Cited by 95
Medical Marijuana Use in Oncology: A Review
Wilkie, G., Sakr, B., & Rizack, T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0155 · Cited by 94
Häuser, W., Welsch, P., Klose, P., Radbruch, L., & Fitzcharles, M. (2019) · Der Schmerz · doi:10.1007/s00482-019-0373-3 · Cited by 108
Management of Nausea and Vomiting in the Cancer Patient
Frytak, S. (1981) · JAMA · doi:10.1001/jama.1981.03310290055028 · Cited by 93
The Selective Cannabinoid Antagonist SR 141716A Blocks Cannabinoid-Induced Antinociception in Rats
Lichtman, A. H., & Martin, B. R. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00121-9 · Cited by 93
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
Karst, M., Wippermann, S., & Ahrens, J. (2010) · Drugs · doi:10.2165/11585260-000000000-00000 · Cited by 104
Interaction of the cannabinoid and opioid systems in the modulation of nociception
Welch, S. P. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782794 · Cited by 91
Metadata
- Authors
- Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A.
- Affiliations
- University of Iowa (US)
- ORCID
- Avery, David H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1975-07
- Volume
- 18
- Issue
- 1
- Pages
- 84-89
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2415446085
- Cited by
- 378
- References
- 4
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 10 · 2020: 16 · 2019: 10 · 2018: 18 · 2017: 11 · 2016: 15 · 2015: 7 · 2014: 11 · 2013: 8 · 2012: 11
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- delta-9-tetrahydrocannabinol, codeine, analgesia, cancer pain, oral administration, adverse drug reactions, sedation, dose-response relationship, drug tolerance
- MeSH terms
- Analgesics, Aspirin, Cannabis, Clinical Trials as Topic, Codeine, Drug Therapy, Combination, Female, Humans, Male, Phytotherapy, Middle Aged, Neoplasms, Pain, Palliative Care, Placebos, Dextropropoxyphene, Dronabinol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.